ESTRECTIPE 3 1 MAR 2006 estimated Electer Office (DO/EO/US) Concerning a Submission Under 35 U.S.C. 37 14042 U. Sulfsific for PTO-1390 (Rev. 07-2005) "Transmittal Letter to the United States De Approved for use through 3/31/2007." OMB 0651-0021

Approved	tor us	e through 3/31/200	/. ON
	•	U. S.	PAT
033106			U.S.

ENT AND TRADEMARK OFFICE U.S. DEPARTMENT OF COMMERCE ATTORNEY'S DOCKET NUMBER

MS0044P

TRANSMITTAL LETTER DESIGNATED/ELECTE CONCERNING A FILIN	CD OFFICE (DO/EO/US)	U.S. APPLICATION NO. (If known, see 37 CFR 1.5)  10/5/4655					
INTERNATIONAL APPLICATION NO.	INTERNATIONAL FILING DATE	PRIORITY DATE CLAIMED					
PCT/US2004/034374	October 18, 2004	October 22, 2003					
TITLE OF INVENTION							
PRODRUGS OF DIARYL-2-(5H)-FU	RANONE CYCLOOXYGENASE-2 I	NHIBITORS					
APPLICANT(S) FOR DO/EO/US							
Jeannie M Arruda, Benito Munoz and Brian A.							
Applicant herewith submits to the other information:	United States Designated/Elected Of	fice (DO/EO/US) the following items and					
1. X This is a FIRST submission	This is a FIRST submission of items concerning a filing under 35 U.S.C. 371.						
2. This is a <b>SECOND</b> or <b>SUBS</b>	This is a SECOND or SUBSEQUENT submission of items concerning a filing under 35 U.S.C. 371.						
3. This is an express request to include items (5), (6), (9) and		s [35 U.S.C. 371(f)]. The submission must					
4. X The US has been elected (Pe							
5. X A copy of the International A	A copy of the International Application as filed [35 U.S.C. 371(c)(2)]						
a. is attached hereto (rec							
b. has been communicat	b. has been communicated by the International Bureau.						
c. X is not required, as the	c. X is not required, as the application was filed in the United States Receiving Office (RO/US).						
6. An English language transla a. is attached hereto	tion of the International Application as	filed [35 U.S.C. 371(c)(2)].					
b. has been previously s	ubmitted under 35 U.S.C. 154(d)(4).						
	f the International Application under Fequired only if not communicated by t	-					
b. have been communic	ated by the International Bureau.						
	however, the time limit for making suc	h amendments has NOT expired.					
d. X have not been made a	nd will not be made.						
8. An English language transla	tion of the amendments to the claims u	nder PCT Article 19 [35 U.S.C. 371(c)(3)].					
9. An oath or declaration of the	e inventor(s) [35 U.S.C. 371(c)(4)].						
		Preliminary Examination Report under PCT					
Article 36 [35 U.S.C. 371(c) Items 11 to 20 below concern other	(3)]. · document(s) or information include	ed:					
_	Statement under 37 CFR 1.97 and 1.98						
12. An assignment document for is included.	recording. A separate cover sheet in	compliance with 37 CFR 3.28 and 3.31					
13. X A preliminary amendment.		·					
14. An Application Data Sheet u	ander 37 CFR 1.76.						
15. A substitute specification.							
16. A power of attorney and/or of	change of address letter.						
17. A computer-readable form of	f the sequence listing in accordance w	ith PCT Rule 13ter.2 and 37 CFR 1.821 - 1.825.					
18. A second copy of the publish	ned International Application under 35	U.S.C.154(d)(4).					
19. A second copy of the English	h language translation of the internatio	nal application under 35 U.S.C.154(d)(4).					
20. Other items or information:							

Substitute for PTO-1390 (Rev. 07-2005) "Transmittal Letter to the Office Designated/Elected/Office (26)/E9/OF) Concerning a Substitute for PTO-1390 (Rev. 07-2005) "Transmittal Letter to the Office Designated/Elected/Office (26)/E9/OF) Concerning a Substitute for PTO-1390 (Rev. 07-2005) "Transmittal Letter to the Office Designated/Elected/Office (26)/E9/OF) Concerning a Substitute for PTO-1390 (Rev. 07-2005) "Transmittal Letter to the Office Designated/Elected/Office (26)/E9/OF) Concerning a Substitute for PTO-1390 (Rev. 07-2005) "Transmittal Letter to the Office Designated/Elected/Office (26)/E9/OF) Concerning a Substitute for PTO-1390 (Rev. 07-2005) "Transmittal Letter to the Office Designated/Elected/Office (26)/E9/OF) Concerning a Substitute for PTO-1390 (Rev. 07-2005) "Transmittal Letter to the Office Designated/Elected/Office (26)/E9/OF) Concerning a Substitute for PTO-1390 (Rev. 07-2005) "Transmittal Letter to the Office Designated/Elected/Office (26)/E9/OF) Concerning a Substitute for PTO-1390 (Rev. 07-2005) "Transmittal Letter to the Office Designated/Elected/Office (26)/E9/OF) Concerning a Substitute for PTO-1390 (Rev. 07-2005) "Transmittal Letter to the Office Designated (26)/E9/OF) (Rev. 07-2005) "Transmittal Letter to the Office Designated (26)/E9/OF) (Rev. 07-2005) "Transmittal Letter to the Office Designated (26)/E9/OF) (Rev. 07-2005) "Transmittal Letter to the Office Designated (26)/E9/OF) (Rev. 07-2005) "Transmittal Letter to the Office Designated (26)/E9/OF) (Rev. 07-2005) "Transmittal Letter to the Office Designated (26)/E9/OF) (Rev. 07-2005) "Transmittal Letter to the Office Designated (26)/E9/OF) (Rev. 07-2005) "Transmittal Letter to the Office Designated (26)/E9/OF) (Rev. 07-2005) "Transmittal Letter to the Office Designated (26)/E9/OF) (Rev. 07-2005) "Transmittal Letter to the Office Designated (26)/E9/OF) (Rev. 07-2005) "Transmittal Letter (26)/E9/OF

		mugh 3/31/200		51-0021			·		
U.S. APPLICATION N	O. (If kno	wn, see 37 CF	R 1.5)	INTERN	ATIONAL APPLICATION NO.			ATTORNEY'S DOC	KET NUMBER
10/5	74	655	<b>5</b> PCT/US2004/034374		MS0044P				
The following	fees are	submitted:			•			CALCULATIONS	PTO USE ONLY
21. X Basic nat	ional fee	<b></b>			•••••	•••••	\$300	\$300.00	
22. Examination fee (37 CFR 1.492(c))					-				
If the written opinion prepared by ISA/US or the international preliminary examination report prepared by IPEA/US indicates all claims satisfy provisions of PCT Article 33(1)-(4)									
				•••••	<del></del>		5200	\$0.00	
23. Search fee (37 CFR 1.492(b))  If the written opinion of the ISA/US or the international preliminary examination report prepared by IPEA/US indicates all claims satisfy provisions of PCT Article 33(1)-(4)						า	\$0.00		
International Search Report prepared by an ISA other than the US and provided to the Office or previously communicated to the US by the IB									
All other situations			•••••					0200.00	
Additional fee for	or enecif	ication and d	rawings file	ed in nan	TOTAL OF	•		\$300.00	
Additional fee for specification and drawings filed in paper over 100 sheets (excluding sequence listing or computer program listing filed in an electronic medium). The fee is \$250 for each additional 50 sheets of paper or fraction thereof.									
Total Sheets	Extra	Sheets			dditional 50 or fraction to a whole number)		RATE		***
38 - 100 =	0	/50	0		0	X	\$250.00	\$0.00	
Surcharge of \$130.00 priority date [37 CFI		_	th or decla	ration la	ter than 30 months from the e	arliest	claimed		
CLAIMS	1.432(	NUMBER	FILED		NUMBER EXTRA		RATE		
Total Claims			20	- 20 =	0	X	\$50.00	\$0.00	
Independent Claims			1	- 3 =	0	$\frac{x}{x}$	\$200.00	\$0.00	
•	>E> IT (1)	L A D 4(0) (15			<u> </u>			\$0.00	
MULTIPLE DEPENDENT CLAIM(S) (if applicable) + \$360.00				\$360.00					
-	•	TOTAL OF	ABOVE C	ALCUL	ATIONS (SUBTOTAL)		= .	\$300.00	
Processing fee of \$130.00 for furnishing the English translation later than 30 months from the earliest claimed priority date (37 CFR 1.492(f)].									
,	TOTAL NATIONAL FEE =				=	\$300.00			
Fee for recording the enclosed assignment [37 CFR 1.21(h)]. The assignment must be accompanied by an appropriate cover sheet (37 CFR 3.28, 3.31).\$40.00 per property.					+		,		
accompanied by an e	рргорги		(57 0110	5.50, 5.0	TOTAL FEES ENCLO	SED	=	\$300.00	
								Amount to be	
								refunded: Amount to be	
								charged:	
b. 🔀 Please	charge 1	my Deposit	Account 1	No. <u>13-</u> 2	to cover the above fees is 2755 in the amount of \$30			cover the above fees.	
c 🔀 The Co	mmissi		by authori	zed to d	charge any additional fees				
overpay		•			2755. A duplicate copy of				D 1 137(a) av
					CFR 1.494 or 1.495 has n tional Application to pen			ition to revive 137 Cr	K 1.137(a) 01
SEND ALL COI	• • • • • • • • • • • • • • • • • • • •		TO:						
<u> </u>						,	1 .	. ()	
MERCK & CO., Patent Departme		50-30					into	Jan 1	
P.O. Box 2000	, ICI	JJ-J <del>U</del>			SI	<u>ري</u> GNA٦	<i>IVIM</i> TURE	- The	
126 East Lincoln							-	V	
Rahway, New Je	rsey 0	/065-0970			<u>Cu</u>	rtis C.	. Panzer		
		_			N/	ME			
DATE: March				_	33.	752			
PHONE #: <u>(73</u>	<u>2) 594-</u>	3199		_			TRATION NU	JMBER	

## IAP2013054PCIPTO 04 APR 2006

## Page 1A of TRANSMITTAL LETTER TO THE UNITED STATES DESIGNATED/ELECTED OFFICE (DO/EO/US) CONCERNING A FILING UNDER 35 U.S.C. 371

-	
International Appln No.:	PCT/US2004/034374
International Filing Date:	18 October 2004
Priority Date:	22 October 2003
Title:	PRODRUGS OF DIARYL-2-(5H)-FURANONE CYCLOOXYGENASE-2 INHIBITORS
Inventors:	Jeannie M. Arruda, Benito Munoz and Brian A. Stearns

MS0044P

**Attorney Docket No.:** 

EXPRESS MAIL CERTIFICATE
DATE OF DEPOSIT 31 March 2006
EXPRESS MAIL NO. EV660609461US
I HEREBY CERTIFY THAT THIS CORRESPONDENCE IS BEING DEPOSITED WITH THE UNITED STATES POSTAL SERVICE AS EXPRESS MAIL "POST OFFICE TO ADDRESSEE" ON THE ABOVE DATE IN AN ENVELOPE ADDRESSED TO COMMISSIONER FOR PATENTS P.O. BOX 1450, ALEXANDRIA, VIRGINIA 22313-1450.
MAILED BY THE CONTRACT DATE STORY OF